container

Summer Street Research Partners Announces Hiring of Jack Kiernan to Lead Its Life Sciences Investment Banking Franchise

Addition of highly experienced banker builds upon firm’s strong investment banking momentum.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend

Boston, Massachusetts (PRWEB) June 03, 2014

Summer Street Research Partners, a leading healthcare-focused investment bank, today announced that Jack Kiernan has joined the firm as a Managing Director and Head of Life Sciences Investment Banking. He will be based in New York and joins Summer Street with more than 25 years of healthcare investment banking experience.

Most recently, Jack was a Managing Director of Stifel’s healthcare investment banking group. Prior to Stifel, he held similar positions at Cowen and Leerink Swann. Jack was also Head of U.S. Healthcare at Citigroup and built the life sciences investment banking practice at Donaldson, Lufkin & Jenrette. He began his healthcare investment banking career with Merrill Lynch. Jack graduated from Dartmouth College and received an MBA from Harvard Business School.

“We are very excited to welcome Jack to the firm,” said Don Munoz, Head of Investment Banking. “He is a proven performer with deep relationships in the specialty pharmaceutical and biotechnology sectors. Jack’s hiring will expand our footprint in life sciences and accelerate the growth of our investment banking franchise.”

Mr. Kiernan remarked, “I am excited to be joining Summer Street at this dynamic time in the firm’s growth. Summer Street has a unique and differentiated platform driven by our MCRI network of several thousand health care experts. We have an unparalleled capability to finance and advise life sciences companies, and I look forward to contributing to the firm’s success.”

About Summer Street Research Partners

Summer Street Research Partners is an investment banking and securities firm focused exclusively on the healthcare sector. The firm is a trusted advisor to buy-side institutional clients and healthcare companies alike. Our vision is to help lead investment capital toward innovative products improving human life.